Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GeneDx Holdings Corp. (WGS)

GeneDx Q2 revenue rises 11% to $114.4 million; GAAP net loss of $17.7 million

Mixed Impact 3 of 5 earnings Written later

GeneDx reported second quarter 2026 revenue of $114.4 million, up 11% year-over-year, with exome and genome volume up 32%. It posted a GAAP net loss of $17.7 million, compared with net income of $10.8 million a year earlier, and reaffirmed full-year 2026 revenue guidance of $475 to $490 million, while its loan facility with Blackstone was expanded to $150.0 million.

Key points

  • Q2 2026 revenue was $114.4 million, up 11% year-over-year; exome and genome test volume was 30,785, up 32%.
  • GAAP net loss was $17.7 million ($0.60 per share) versus net income of $10.8 million in Q2 2025; adjusted net income was $0.4 million versus $16.4 million a year earlier.
  • Full-year 2026 revenue guidance of $475 to $490 million was reaffirmed; third-quarter revenue guidance is $122 to $124 million.
  • On August 3, 2026, the Blackstone loan facility was increased to $150.0 million, and pro forma cash is approximately $188 million.

The filing

CompanyGeneDx Holdings Corp. (WGS)
Form8-K, current report
Filed with the SECAug 3, 2026, 4:14 PM ET
Accession number0001628280-26-051852

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.